PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 10 - Any |
| Updated: | 4/2/2016 |
Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with
sickle cell disease who are otherwise healthy.
sickle cell disease who are otherwise healthy.
Phase 1, single center, open label, multiple-dose study consisting of a screening period
followed by four weeks of treatment. At least 12 male and female patients, 10 years of age
or older, with sickle cell disease but otherwise healthy, will be enrolled in the study.
PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and
L-proline following the first dose of orally administered L-citrulline and after four weeks
of twice daily administration of the drug.
PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and
E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of
vascular function.
followed by four weeks of treatment. At least 12 male and female patients, 10 years of age
or older, with sickle cell disease but otherwise healthy, will be enrolled in the study.
PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and
L-proline following the first dose of orally administered L-citrulline and after four weeks
of twice daily administration of the drug.
PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and
E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of
vascular function.
Inclusion Criteria:
1. Male or female, 10 years of age or older on the day of dosing, and generally healthy
as determined by medical history, physical examination, and laboratory test values
2. Diagnosis of sickle cell anemia (Hb SS)
3. For female of child-bearing potential, a negative serum pregnancy test and using an
adequate method of contraception
4. Has signed and received a copy of the written informed consent form approved by the
investigator’s Institutional Review Board (IRB), understands the purposes and risks
of the study and agrees to follow the restrictions and schedule of procedures as
defined by this protocol
Exclusion Criteria:
1. History of sickle-cell–related pain crisis within two weeks of study
2. Pregnant or breast feeding
3. Transfusion within last 90 days
4. Creatinine >1.5 X upper limit of normal
5. SGPT > 2 X upper limit of normal
6. History of allergic reaction to arginine or citrulline product
7. Requires chronic medication other than study drug that cannot be discontinued during
the study period
8. Unable to take or tolerate oral medications
9. Unreliable venous access
10. Noncompliant with regular care
11. Participation in an investigational drug or medical device study within previous 30
days
12. In the opinion of the investigator is not a good candidate for participation in the
study
We found this trial at
1
site
Pittsburgh, Pennsylvania 15213
Click here to add this to my saved trials
